(2Z)-nonenyl nonanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2Z)-nonenyl nonanoate
• 英文别名: [(Z)-non-2-enyl] nonanoate
• 化学式: C₁₈H₃₄O₂
• 分子量: 282.467
• InChiKey: MAXNGHYWDBKPBN-SQFISAMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  20
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  壬酸 、 顺-2-壬烯-1-醇 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以69%的产率得到(2Z)-nonenyl nonanoate
  参考文献：
  名称：

  两种蠕虫蛾（Carposinidae）酯信息素类似物的合成及生物学测试。

  摘要：

  合成了一系列用于类胡萝卜素的酯信息素类似物，并对其生物学活性进行了评估。这些类似物旨在利用在该家族中发现的（7 Z）-α酮11-酮的结构共性。对两种害虫种类进行了类似物测试：异花杂种和杂种Coscinoptycha improbana。其中的两个类似物，（2 Z）-壬烯基壬酸酯和（4 Z）-庚基十一烯酸酯，引起显着的脑电图反应。仅（4 Z）-十一碳烯酸庚酯在单个sensillum记录中对两种蛾类都给出了一致的响应。分别对这两种类似物以及与两种蛾类中每种信息素的结合进行了野外诱捕试验。蛾类物种对单独的任一类似物均未观察到吸引力。然而，当（4 Z）-十一碳烯酸十一碳酸酯与信息素偶联时，它对红花丝藻产生了强大的抑制作用，使雄蛾的诱捕量降低了95％以上。没有抑制作用的雄性蛾陷阱捕获在C. improbana。

  DOI：

  10.1021/acs.jafc.0c04131

文献信息

• [EN] BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES POUR L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086354A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其中在阳离子脂质的脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以掺入脂质粒子中，用于递送一种活性剂，例如核酸。本发明还涉及包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选的甾醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。
• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20160009637A1

  公开（公告）日：2016-01-14

  The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其具有位于脂质基团（例如，疏水链）的中部或远端部位的一个或多个可生物降解的基团。这些阳离子脂质可以被纳入脂质颗粒中，用于传递活性剂，例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质颗粒。脂质颗粒还可以进一步包含治疗剂，如核酸。
• [EN] FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS LIPIDIQUES FONCTIONNELS ET LEURS UTILISATIONS
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2021237055A1

  公开（公告）日：2021-11-25

  The present disclosure relates to compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

  本公开涉及化合物、组合物和用于传递治疗、诊断或预防性药剂（例如核酸）的方法。
• LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20140308304A1

  公开（公告）日：2014-10-16

  The present invention relates to novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
• IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150306039A1

  公开（公告）日：2015-10-29

  The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.